A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 169-176

  Loconte, Noelle K ^a   Razak, Albiruni R A ^b   Ivy, Percy ^c   Tevaarwerk, Amye ^a   Leverence, Rachael ^a,d   Kolesar, Jill ^a,d   Siu, Lillian ^b   Lubner, Sam J ^a   Mulkerin, Daniel L ^a   Schelman, William R ^a   Deming, Dustin A ^a   Holen, Kyle D ^a   Carmichael, Lakeesha ^a,d   Eickhoff, Jens ^a,d   Liu, Glenn ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Capecitabine; Colorectal cancer; Phase 1; RO4929097

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; 2,2-DIMETHYL-N-(6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUOROPROPYL)MALONAMIDE; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; DEOXYCYTIDINE; FLUOROURACIL; PRODRUG; SECRETASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BLEEDING; CARCINOID; CHILL; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LEG PAIN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SOLID TUMOR; TREATMENT RESPONSE; UTERINE CERVIX CANCER; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASMS;

AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAZEPINES; CAPECITABINE; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PRODRUGS;

EID: 84922079770     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0166-6     Document Type: Article

References (23)

1. Purow B (2012) Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 727:305-19
2. Tolcher AW, Messersmith WA, Mikulski SM et al (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30:2348-2353
3. Aster JC, Pear WS, Blacklow SC (2008) Notch signaling in leukemia. Annu Rev Pathol 3:587-613
4. Staal FJ, Langerak AW (2008) Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. Haematologica 93:493-497
5. Dickson BC, Mulligan AM, Zhang H et al (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20:685-693
6. Reedijk M, Odorcic S, Chang L et al (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65:8530-8537
7. Reedijk M, Pinnaduwage D, Dickson BC et al (2008) JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 111:439-448
8. Massi D, Tarantini F, Franchi A et al (2006) Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 19:246-254
9. Okuyama R, Tagami H, Aiba S (2008) Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci 49:187-194
10. Pinnix CC, Herlyn M (2007) The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 20:458-465
11. Chen Y, De Marco MA, Graziani I et al (2007) Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67:7954-7959
12. Konishi J, Kawaguchi KS, Vo H et al (2007) Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67:8051-8057
13. Peacock CD, Watkins DN (2008) Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 26:2883-2889
14. Meng RD, Shelton CC, Li YM et al (2009) Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69(2):573-82
15. Luistro L, He W, Smith M et al (2009) Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69(19):7672-80
16. Tolcher AW, Messersmith WA, Mikulski SM et al (2012) Phase I study of RO4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30(19):2348-2353
17. O'Shaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-flurouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247-54
18. Twelves C, Scheithauer W, McKendrick J et al (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23(5):1190-7
19. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097-106
20. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-47
21. Mulkerin D, LoConte NK, Holen KD et al (2009) A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs 27(5):461-8
22. Olsauskas-Kuprys R, Zlobin A, Osipo C (2013) Gamma secreatase inhbitors of Notch signaling. Onco Targets Ther 6:943-955
23. Sahebjam S, Bedard PL, Castonguay V et al (2013) A phase I study of the combination of RO4929097 and cediranib in paitnets with advanced solid tumors. Br J Cancer 109:943-949